INHIBITEX REPORTS ADVANCEMENTS IN ITS CLINICAL TRIALS

Inhibitex has announced that enrollment in its ongoing Phase III clinical trial of Veronate for the prevention of hospital-associated infections in very low birth weight infants has outpaced the company's initial expectations and that it has enrolled 684, or more than one-third, of the 2,000 patients it intends to enroll in the trial.

Additionally, the company reported that an independent data safety monitoring board met to review safety and other data available from the first 500 patients enrolled in the trial and unanimously recommended that the trial proceed as designed without modification.

The company also has completed enrollment in its 60-patient Phase II clinical trial of Aurexis in patients with documented Staphylococcus aureus bloodstream infections.